Table 1 General characteristics of the patient cohort.
From: Cytoplasmic HIF-2α as tissue biomarker to identify metastatic sympathetic paraganglioma
sPGL (%) | HN-PGL (%) | PCC (%) | PPGL (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|
Gender | Female (%) | Male (%) | Female (%) | Male (%) | Female (%) | Male (%) | Female (%) | Male (%) | |
6 (46) | 7 (54) | 6 (46) | 7 (54) | 68 (55) | 55 (45) | 80 (54) | 69 (46) | ||
Age of diagnosis | Mean age (range) | Mean age (range) | Mean age (range) | Median age (range) | |||||
54 (32–72) | 47 (22–76) | 51 (15–83) | 53 (15–83) | ||||||
Diagnosis | 13 (9) | 13 (9) | 123 (82) | 149 (100) | |||||
Metastatic status | Non-metastatic (%) | Metastatic (%) | Non-metastatic (%) | Metastatic (%) | Non-metastatic (%) | Metastatic (%) | Non-metastatic (%) | Metastatic (%) | |
7 (54) | 6 (46) | 13 (100) | 0 (0) | 118 (96) | 5 (4) | 138 (93) | 11 (7) | ||
Tumour location | Non-metastatic (%) | Metastatic (%) | Non-metastatic (%) | Metastatic (%) | Non-metastatic (%) | Metastatic (%) | Non-metastatic (%) | Metastatic (%) | |
Adrenal gland | – | – | – | – | 118 (96) | 5 (4) | 118 (79) | 5 (2) | |
Head and neck | – | – | 13 (100) | 0 (0) | – | – | 13 (9) | 0 (0) | |
Thorax or abdomen | 7 (54) | 6 (46) | – | – | – | – | 7 (5) | 6 (5) | |
Biochemical phenotype | Non-metastatic (%) | Metastatic (%) | Non-metastatic (%) | Metastatic (%) | Non-metastatic (%) | Metastatic (%) | Non-metastatic (%) | Metastatic (%) | Total (%) |
Unknown | 3 (100) | 0 (0) | – | – | 15 (94) | 1 (6) | 18 (95) | 1 (5) | 19 (100) |
Biochemically silent | 2 (20) | 3 (30) | 13 (100) | 0 (0) | 3 (3) | 0 (0) | 18 (14) | 3 (2) | 21 (16) |
Hormone secreting | 2 (20) | 3 (30) | – | – | 100 (93) | 4 (4) | 102 (78) | 7 (5) | 109 (84) |
Adrenergic | – | – | – | – | 63 (59) | 1 (1) | 63 (48) | 1 (1) | 64 (49) |
Noradrenergic | 2 (20) | 3 (30) | – | – | 36 (33) | 2 (2) | 38 (29) | 5 (3) | 43 (33) |
Dopaminergic | – | – | – | – | 1 (1) | 1 (1) | 1 (1) | 1 (1) | 1 (2) |
Mutation/diagnosis | Non-metastatic (%) | Metastatic (%) | Non-metastatic (%) | Metastatic (%) | Non-metastatic (%) | Metastatic (%) | Non-metastatic (%) | Metastatic (%) | Total (%) |
Unknown | 1 (33) | 2 (67) | 9 (100) | 0 (0) | 36 (100) | 0 (0) | 46 (96) | 2 (4) | 48 (100) |
No mutation | 4 (40) | 0 (0) | – | – | 47 (54) | 3 (4) | 51 (51) | 3 (3) | 54 (54) |
Somatic or germline mutations | 2 (20) | 4 (40) | 4 (100) | 0 (0) | 35 (40) | 2 (2) | 41 (40) | 6 (6) | 47 (46) |
SDHx | 1 (10) | 4 (40) | 4 (100) | 0 (0) | 2 (2) | 2 (2) | 7 (6) | 6 (6) | 13 (12) |
EPAS1 | 1 (10) | 0 (0) | – | – | – | – | 1 (1) | 0 (0) | 1 (1) |
RET | – | – | – | – | 17 (20) | 0 (0) | 17 (17) | 0 (0) | 17 (17) |
VHL | – | – | – | – | 6 (7) | 0 (0) | 6 (6) | 0 (0) | 6 (6) |
HRAS | – | – | – | – | 2 (2) | 0 (0) | 2 (2) | 0 (0) | 2 (2) |
NF1 | – | – | – | – | 8 (9) | 0 (0) | 8 (8) | 0 (0) | 8 (8) |
